AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11965231
Drug: Radiolabeled antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiolabeled antibodies
Trial: 11965231
Drug: Radiolabeled antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiolabeled antibodies used in conjunction with conditioning regimens
Trial: 2679680
Drug: sulbactam/ampicillin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulbactam/ampicillin (1 g:2 g) administered intravenously every 8 h
Trial: 2679680
Drug: cefotetan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cefotetan (2 g) administered intravenously every 12 h
Trial: 19548446
Drug: Shuxuetong Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuxuetong Injection (SXT)
Trial: 428840
Drug: Actihaemyl (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actihaemyl (6 weeks, twice weekly 10 ml i.v.)
Trial: 30741761
Drug: Routine physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine physical therapy alone (Control)
Trial: 30741761
Drug: Ergonomic latex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergonomic latex pillow with physical therapy
Trial: 9862576
Drug: Doxorubicin 75
RxNorm normalized name: DOXOrubicin 75 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 75 mg m(‐2) on day 1 (112 patients)
Trial: 9862576
Drug: Epirubicin 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 150 mg m(‐2) on day 1 (111 patients)
Trial: 9862576
Drug: Epirubicin 50
RxNorm normalized name: epiRUBicin 50 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 50 mg m(‐2) on days 1, 2, and 3 (111 patients)
Trial: 7623523
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) at low doses (30 mg and 100 mg)
Trial: 7623523
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) at moderate doses (400 mg)
Trial: 67128
Drug: Rectal oxymorphone
RxNorm normalized name: oxymorphone hydrochloride Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal oxymorphone
Trial: 26253566
Drug: Initial dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dual therapy (combination therapy)
Trial: 22103436
Drug: Initial monotherapy
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial monotherapy
Trial: 16879829
Drug: 1.35 g
RxNorm normalized name: Octinoxate 1.35 g in 30 g TOPICAL CREAM [LBel Supremacie Teint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.35 g EPA/day
Trial: 16879829
Drug: 2.7 g
RxNorm normalized name: Magnesium 420 MG/2.7 GM Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.7 g EPA/day
Trial: 16879829
Drug: 4.05 g
RxNorm normalized name: ZINC OXIDE 24.05 g in 100 g TOPICAL CREAM [Hi papa KIDS MINERAL FACE SUNSCREEN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.05 g EPA/day
Trial: 16879829
Drug: EPA (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA (all doses)
Trial: 16879829
Drug: Highest dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest dose of EPA
Trial: 16879829
Drug: Increased EPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased EPA (all doses)
Trial: 11386610
Drug: Single 10‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 10‐mg dose of diazepam
Trial: 11386610
Drug: Drug abusers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug abusers starting a prison sentence
Trial: 9739972
Drug: Oral famciclovir
RxNorm normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral famciclovir (125 mg or 250 mg 3 times daily or 250 mg twice daily)
Trial: 2522371
Drug: 5% glucose
RxNorm normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% glucose containing 10 U l‐1 insulin
Trial: 2522371
Drug: 10% glucose
RxNorm normalized name: Dextrose 10% Oral Solution [SIMILAC 10% GLUCOSE WATER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% glucose with 40 U l‐1 insulin
Trial: 8679756
Drug: Propranolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (10 mg)
Trial: 5792911
Drug: Saline (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.9% solution, 10 ml)
Trial: 26693643
Drug: Milk-based liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk-based liquid meal supplement (Sustagen Sport)
Trial: 25547902
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg/d orally, intermittent administration on days 2 to 16 every 21 days, combined with docetaxel 75 mg/m² every 21 days
Trial: 25547902
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg/d orally, administered continuously
Trial: 12580986
Drug: Gliclazide MR
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide MR (30 mg initial dose)
Trial: 7159686
Drug: Sustained-release quinidine
RxNorm normalized name: quinidine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release quinidine tablet (300 mg)
Trial: 7159686
Drug: Oral quinidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral quinidine sulfate solution (300 mg)
Trial: 29726951
Drug: Walnut consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut consumption (42 g walnuts/d)
Trial: 25536669
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rhGH) 3 mg daily
Trial: 25536669
Drug: rosiglitazone (Rosi)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rosiglitazone (Rosi) 4 mg twice daily
Trial: 25536669
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rhGH and Rosi
Trial: 23582949
Drug: Intermittent Hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent Hormonal Therapy (IHT) with cyproterone acetate (CPA) 200 mg/d for 2 weeks, then monthly LHRH analogue plus CPA 200 mg/d.
Trial: 23582949
Drug: Continuous Maximal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Maximal Androgen Blockade (MAB) with CPA 200 mg/d plus monthly LHRH analogue.
Trial: 24009704
Drug: Mindfulness based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness based cognitive therapy (MBCT)
Trial: 18698881
Drug: Slow-escalation treprostinil
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Slow-escalation treprostinil dosing regimen
Trial: 18698881
Drug: Rapid-escalation treprostinil
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rapid-escalation treprostinil dosing regimen
Trial: 16538016
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia maintained with 2 L of oxygen, 4 L of nitrous oxide, and 1% to 3% isoflurane
Trial: 12824786
Drug: GM‐CSF (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM‐CSF (300 microg by subcutaneous injection three times weekly for 4 weeks)
Trial: 10632688
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (lidocaine 2.5% and prilocaine 2.5%)
Trial: 10632688
Drug: ELA-Max cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELA-Max cream (lidocaine 4%)
Trial: 10632688
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia (EMLA and ELA-Max combined)
Trial: 8389667
Drug: Ifosfamide 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 2.0 g/m2 days 1 to 3 with cisplatin 33 mg/m2 days 1 to 3
Trial: 8389667
Drug: Ifosfamide 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 2.5 g/m2 days 1 to 3 with cisplatin 33 mg/m2 days 1 to 3
Trial: 8389667
Drug: Ifosfamide 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 2.0 g/m2 days 1 to 3
Trial: 8389667
Drug: Ifosfamide 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 2.5 g/m2 days 1 to 3
Trial: 3555033
Drug: Intravenous tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous tobramycin plus azlocillin
Trial: 6151842
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of temazepam
Trial: 6138061
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of flurazepam
Trial: 28929925
Drug: Participant-directed occupational
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant-directed occupational therapy intervention
Trial: 15961761
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m(2) plus ifosfamide 5 g/m(2) during 24 hours and cisplatin 75 mg/m(2) every 3 weeks for three courses (TIP)
Trial: 15961761
Drug: Ifosfamide 5
RxNorm normalized name: ifosfamide 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 5 g/m(2) during 24 hours plus cisplatin 75 mg/m(2) (IP)
Trial: 11992097
Drug: PNU-83757 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNU-83757 (10 mcg, 60-140 mcg)
Trial: 19686479
Drug: Total Intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Intravenous Anaesthesia (TIVA)
Trial: 22169620
Drug: Menaquinone-7 (vitamin
RxNorm normalized name: menaquinone-7 (vitamin K2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menaquinone-7 (vitamin K(2)) treatment at 45, 135, or 360 μg/d for 6 weeks
Trial: 18236186
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg ibandronate (1 mL) applied to the tibial bone surface 1 min before cementation
Trial: 18236186
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL saline applied to the tibial bone surface 1 min before cementation
Trial: 8586527
Drug: i.v. essential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. essential amino acids (EAA) solution 13.4 g daily + dopamine i.v. 2 micrograms/kg/min + 20% hypertonic glucose solution 500 ml/d
Trial: 8586527
Drug: dopamine i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dopamine i.v. 2 micrograms/kg/min + 20% hypertonic glucose solution 500 ml/d
Trial: 2527048
Drug: glutamyl-L-dopa (gludopa)
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: glutamyl-L-dopa (gludopa)
Trial: 782685
Drug: Extended maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended maintenance CO treatment
Trial: 31104005
Drug: Mulligan's mobilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mulligan's mobilization with movement (MWM), exercise, and cold therapy
Trial: 21665501
Drug: 5% povidone-iodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% povidone-iodine preparation with no regard to eyebrows (Group A)
Trial: 21665501
Drug: 5% povidone-iodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% povidone-iodine preparation with eyebrows excluded (Group B)
Trial: 21665501
Drug: 5% povidone-iodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% povidone-iodine preparation with bladed lid speculum (Group C)
Trial: 21665501
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not explicitly defined, but implied as standard preparation)
Trial: 16935870
Drug: Azimilide (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azimilide (125 mg o.d.)
Trial: 16935870
Drug: Sotalol (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (160 mg b.i.d.)
Trial: 15342288
Drug: Immediate-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release niacin (3,000 mg/day)
Trial: 15342288
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin (1,500 mg/day)
Trial: 8395712
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparins (LMWH) administered subcutaneously
Trial: 8395712
Drug: Outpatient LMWH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient LMWH therapy
Trial: 2868659
Drug: Alpha blocker
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha blocker (prazosin)
Trial: 6143471
Drug: Diuretic (hydrochlorothiazide)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diuretic (hydrochlorothiazide)
Trial: 2201721
Drug: Zopiclone 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zopiclone 15 mg
Trial: 12698315
Drug: Water (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (750 ml)
Trial: 12698315
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (750 ml)
Trial: 8736053
Drug: Rhinomer (cleansing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhinomer (cleansing preparation of isotonic, sterile, undiluted sea water)
Trial: 8736053
Drug: Prorhinel (marketed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prorhinel (marketed solution containing an antiseptic agent)
Trial: 26026580
Drug: Ramelteon (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon (8 mg nightly for 3 weeks)
Trial: 25227477
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy during labor
Trial: 21103989
Drug: 35-g/m2 titanized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35-g/m2 titanized polypropylene mesh (Group A)
Trial: 21103989
Drug: 16-g/m2 titanized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16-g/m2 titanized polypropylene mesh (Group B)
Trial: 18612886
Drug: Younger age
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Younger age and history of outpatient psychological treatment
Trial: 15820760
Drug: O-[11C]methyl-L-tyrosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O-[11C]methyl-L-tyrosine
Trial: 2128094
Drug: Phentolamine (1-1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine (1-1.5 mg/min)
Trial: 30808625
Drug: golimumab (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: golimumab (50 mg SC monthly) + MTX (n=26)
Trial: 25424398
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) - 16 weekly sessions
Trial: 18440534
Drug: Metformin (1700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1700 mg/day for 6 months)
Trial: 18440534
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) (50 mg/day, increasing doses up to 250 mg/day)
Trial: 17366011
Drug: Ampicillin-sulbactam 18/9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin-sulbactam 18/9 g daily dose (group A)
Trial: 17366011
Drug: Ampicillin-sulbactam 24/12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin-sulbactam 24/12 g daily dose (group B)
Trial: 2906477
Drug: Olsalazine, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olsalazine, 500 mg b.d.
Trial: 2906477
Drug: Sulphasalazine, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphasalazine, 1 g b.d.
Trial: 29685343
Drug: Cabazitaxel Q1W,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel Q1W, 10 mg/m2
Trial: 29685343
Drug: Cabazitaxel Q3W,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel Q3W, 25 mg/m2
Trial: 28093636
Drug: No shock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No shock wave therapy (control group)
Trial: 11214014
Drug: Allopurinol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (1 g)
Trial: 1558834
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg/day for 10 days)
Trial: 3911365
Drug: Antacid group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid group (4 chewable aluminum-magnesium-antacid tablets daily)
Trial: 3911365
Drug: Antacid group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid group
Trial: 31944472
Drug: 18-month weight
RxNorm normalized name: onasemnogene abeparvovec
DrugBank: Onasemnogene abeparvovec (DB15528)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 18-month weight management intervention (reduced calorie diet, 150 min of moderate-vigorous intensity physical activity per week, daily dietary logging, monthly at-home visits by a health educator)
Trial: 23258136
Drug: Landiolol hydrochloride
RxNorm normalized name: Landiolol Hydrochloride
DrugBank: Landiolol (DB12212)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Landiolol hydrochloride (10 µg/kg/min, continuous intravenous)
Trial: 18501909
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg intravenous dose
Trial: 15987918
Drug: Oral capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral capecitabine (1004 patients)
Trial: 14525817
Drug: Ropivacaine 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 60 mg
Trial: 14525817
Drug: Midazolam 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.03 mg/kg prior to ropivacaine
Trial: 8808721
Drug: Ifosfamide 5
RxNorm normalized name: ifosfamide 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 5 g/m2xdx1 and doxorubicin 60 mg/m2xdx1 given every 3 weeks with r‐met Hu G‐CSF (250 micrograms/m2xd)
Trial: 8808721
Drug: Ifosfamide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 1.8 g/m2xdx5 and doxorubicin 60 mg/m2xdx1 given every 4 weeks
Trial: 1419009
Drug: IM ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM ketorolac 30 mg while in the PACU, followed by 15 mg every 6 hours
Trial: 1419009
Drug: IM ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM ketorolac 60 mg while in the PACU, followed by 30 mg every 6 hours
Trial: 1419009
Drug: IV PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV PCA morphine
Trial: 30721941
Drug: Lipid-based micronutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based micronutrient supplement commenced ≥3 months before conception (Arm 1)
Trial: 30721941
Drug: Lipid-based micronutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based micronutrient supplement commenced late in the first trimester of pregnancy (Arm 2)
Trial: 27113302
Drug: Solution-focused approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution-focused approach
Trial: 25136038
Drug: VIS and
RxNorm normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIS and information emphasizing the MMR vaccine's benefits to the child
Trial: 22190555
Drug: Remimazolam (0.30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam (0.30 mg/kg)
Trial: 22190555
Drug: Remimazolam (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam (0.05 to 0.20 mg/kg)
Trial: 16580903
Drug: Midazolam (0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.075 mg/kg)
Trial: 22190555
Drug: Remimazolam (0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam (0.10 and 0.15 mg/kg)
Trial: 9311393
Drug: Thiopental 5
RxNorm normalized name: thiopental 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental 5 mg kg‐1 induction and isoflurane maintenance (Group T/I)
Trial: 9311393
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg kg‐1 induction, 5 mg kg‐1 h‐1 maintenance (Group P5)
Trial: 9311393
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg kg‐1 induction, 10 mg kg‐1 h‐1 maintenance (Group P10)
Trial: 30468145
Drug: Mirtazapine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (15 mg daily for 2 weeks, then 30 mg daily for up to 12 months)
Trial: 25172798
Drug: Korodin(®) (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korodin(®) (20 drops administered four times with 10 min intervals)
Trial: 25172798
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 drops administered four times with 10 min intervals)